Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $7 to $5.
Share
Why It Matters
An analyst thinks LENZ stock is worth less money than before. This shows the company faces real challenges worth watching closely.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.